Skip to main content

Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer

Written by Customer Service on . Posted in Public Companies.

IRVINE, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Operating Officer, effective September 1, 2020.  In his expanded role, Mr. Hykes will now have responsibility for Research, Product Development, Manufacturing, Operations, Quality and Regulatory, in addition to the Commercial functions.
Mr. Hykes joined Inari as Chief Commercial Officer in September 2017.  Prior to Inari, Mr. Hykes served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market.  Prior to Sequent, Mr. Hykes spent twelve years at Medtronic in various roles including the VP of Marketing and VP of Clinical and Regulatory for the AF Solutions business, and Director of Investor Relations.  Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions.  He received his B.B.A. from the University of Wisconsin Madison and an M.B.A. from Harvard Business School.“Drew has had a significant impact on our commercial success over the last three years,” said Bill Hoffman, CEO of Inari Medical. “Under Drew’s leadership, we have rapidly built a highly effective and efficient commercial organization dedicated to improving the lives of patients suffering from venous thromboembolism.  This promotion not only recognizes this record of accomplishment, but his passion for Inari’s mission.”“It’s an honor to continue to help Inari Medical bring new technologies to many more physicians and their patients,” said Hykes. “We have built an outstanding organization, with talented people fully dedicated to changing the lives of patients suffering from life-threatening blood clots.”About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.Inari is focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678 
caroline.corner@westwicke.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.